Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
From a systems biology point of view, the oxidative load must first be reduced before recovery becomes visible
GHK-Cu is non-toxic in vitro at nanomolar to micromolar concentrations
Oral administration of PF-06882961 shows evidence of glucose-lowering in healthy human study participants PF-06882961 was selected as a candidate for clinical studies based on its in vitro and in vivo pharmacologic and disposition profile, including potent agonism of the GLP-1R, preclinical disposition attributes (e.g., low metabolic CL int in human hepatocytes), good safety margins versus the hERG channel (IC 50 = 4.3 M, Table S4) and broad panel screening (Table S8), and selectivity versus related class B GPCRs (Table S9)
Studies suggest that social isolation may exacerbate metabolic dysfunction and impair liver regeneration
US$ 22.93
US$ 29.34
US$ 24.36
)
US$ 27.82
US$ 25.54
US$ 23.70
